Amarantus Financial Statements From 2010 to 2026
Amarantus Bioscience's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Amarantus Bioscience's valuation are provided below:Amarantus Bioscience Holdings does not presently have any fundamental signals for analysis.
This module can also supplement various Amarantus Bioscience Technical models . Check out the analysis of Amarantus Bioscience Correlation against competitors.
Check Amarantus Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amarantus Bioscience's main balance sheet or income statement drivers, such as , as well as many indicators such as . Amarantus financial statements analysis is a perfect complement when working with Amarantus Bioscience Valuation or Volatility modules.
Amarantus |
Amarantus Bioscience Holdings Company EBITDA Analysis
Amarantus Bioscience's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Amarantus Bioscience EBITDA | (20.79 M) |
Most of Amarantus Bioscience's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amarantus Bioscience Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Amarantus Bioscience Holdings reported earnings before interest,tax, depreciation and amortization of (20.79 Million). This is 102.37% lower than that of the Biotechnology sector and 120.76% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.53% higher than that of the company.
Amarantus Bioscience Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amarantus Bioscience's current stock value. Our valuation model uses many indicators to compare Amarantus Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amarantus Bioscience competition to find correlations between indicators driving Amarantus Bioscience's intrinsic value. More Info.Amarantus Bioscience Holdings is the top company in current valuation category among its peers. It is rated fifth in shares outstanding category among its peers creating about 10.36 of Shares Outstanding per Current Valuation. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amarantus Bioscience's earnings, one of the primary drivers of an investment's value.About Amarantus Bioscience Financial Statements
Amarantus Bioscience shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Amarantus Bioscience investors may analyze each financial statement separately, they are all interrelated. The changes in Amarantus Bioscience's assets and liabilities, for example, are also reflected in the revenues and expenses on on Amarantus Bioscience's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York. Amarantus Bioscience operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Amarantus Pink Sheet Analysis
When running Amarantus Bioscience's price analysis, check to measure Amarantus Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amarantus Bioscience is operating at the current time. Most of Amarantus Bioscience's value examination focuses on studying past and present price action to predict the probability of Amarantus Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amarantus Bioscience's price. Additionally, you may evaluate how the addition of Amarantus Bioscience to your portfolios can decrease your overall portfolio volatility.